Tafluprost ethyl amide
CAS No:
1185851-52-8
Molecular Formula：
C24H33F2NO4
Molecular Weight：
437.52
Storage:
Store in a tightly closed container in a cool, dry，Protect from moisture and direct sunlight.
Download Product Documents
If documents are missing, please contact customer service.
Technical Data
| Appearance | Colorless or light yellow oil |
|---|---|
| Identification | The retention time of the major peak in the chromatogram of the sample corresponds to that of the standard solution,as obtained in the related substance. |
| Solubility | Soluble in methanol and ethanol, insoluble in |
| Loss on drying | NMT 1.0% |
| Total impurity | NMT 1.0% |
| Puirty | ≥99.0% |
Description
Taflpostamide, also called Tafluprost ethyl amide, is a synthetic analogue of 17-phenyl trinor Prostaglandin F₂α designed to act as a selective prostaglandin F (FP) receptor agonist. In preclinical studies, it demonstrated potent ocular hypotensive activity, reducing intraocular pressure (IOP) by 25–35% in normotensive and glaucomatous animal models, including rabbits and monkeys, after topical administration. Taflpostamide showed high receptor selectivity, minimal off-target activity, and favorable corneal penetration. Pharmacokinetic analyses indicated rapid ocular absorption with sustained local activity and low systemic exposure. These findings support its potential application as a therapeutic agent for glaucoma or ocular hypertension, providing effective IOP reduction with a promising safety profile.
Tafluprost ethyl amide is a prostaglandin derivative. Tafluprost ethyl amide is capable of reducing intraocular pressure (IOP) and influencing eyelash growth. Tafluprost ethyl amide can be used in antiglaucoma ophthalmic compositions.
Safety Information
GHS
Pictogram:
Signal Word:
Danger
Hazard Statements:
H225 Highly flammable liquid and vapor.
H319 Causes serious eye irritation.
H360 May damage fertility or the unborn child
Precautionary Statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources.
No smoking.
P233 Keep container tightly closed.
P240 Ground / bond container and receiving equipment.
P241 Use explosion-proof [electrical/ventilating/lighting] equipment.
P242 Use non-sparking tools.
P243 Take action to prevent static discharge.
P264 Wash thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing
protection.
P303+P361+P353 If on skin (or hair): Take off immediately all contaminated clothing. Rinse skin with
water [or shower].
P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P337+P313 If eye irritation persists: Get medical advice/attention.
P370+P378 In case of fire: Use CO2, powder or water spray to extinguish.
P403+P235 Store in a well-ventilated place. Keep cool.
P405 Store locked up.
P501 Dispose of contents/container in accordance with local/regional/national/international
regulations.
References
Krupa M, et al. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules. 2017 Jan 31;22(2):217.
Krupa M, Chodyński M, Ostaszewska A, Cmoch P, Dams I. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules. 2017 Jan 31;22(2). pii: E217. doi: 10.3390/molecules22020217. PubMed PMID: 28146132; PubMed Central PMCID: PMC6155834.
Reviews
There are no reviews yet.